Resveratrol and Amyloid-Beta: Mechanistic Insights

Nutrients. 2017 Oct 14;9(10):1122. doi: 10.3390/nu9101122.

Abstract

The amyloid-beta (Aβ) hypothesis that dyshomeostasis between Aβ production and clearance is a very early, key molecular factor in the etiology of Alzheimer's disease (AD) has been proposed and examined in the AD research field. Scientists have focused on seeking natural products or drugs to influence the dynamic equilibrium of Aβ, targeting production and clearance of Aβ. There is emerging evidence that resveratrol (Res), a naturally occurring polyphenol mainly found in grapes and red wine, acts on AD in numerous in vivo and in vitro models. Res decreases the amyloidogenic cleavage of the amyloid precursor protein (APP), enhances clearance of amyloid beta-peptides, and reduces Aβ aggregation. Moreover, Res also protects neuronal functions through its antioxidant properties. This review discusses the action of Res on Aβ production, clearance and aggregation and multiple potential mechanisms, providing evidence of the useful of Res for AD treatment.

Keywords: alzheimer disease; amyloid-beta; blood-brain-barrier; resveratrol; transporter.

Publication types

  • Review

MeSH terms

  • Alzheimer Disease / prevention & control*
  • Amyloid beta-Peptides / metabolism*
  • Antioxidants / pharmacology*
  • Humans
  • Neurons / drug effects
  • Neurons / metabolism
  • Resveratrol
  • Stilbenes / pharmacology*

Substances

  • Amyloid beta-Peptides
  • Antioxidants
  • Stilbenes
  • Resveratrol